Allergan plc said the first of two late-stage trials evaluating its migraine drug ubrogepant met its main goal of relieving pain.
The study known as Achieve I was conducted in 1,327 adult patients who were treated for a single migraine attack of moderate to severe headache intensity.
Statistically significant results show that patients who received the drug experienced freedom from pain, or reduced in headache severity, two hours after the initial dose compared to placebo.
The trial also met its co-primary endpoint of eliminating most bothersome migraine-associated symptoms, such as photophobia, phonophobia or nausea, two hours after taking ubrogepant.
Results of the Achieve II study, the second phase 3 trial for ubrogepant, are expected to be available in the first half of 2018.
Allergan intends to file a new drug application to the U.S. Food and Drug Administration for the drug in 2019.
